ExploreWatchlistsPricing
  1. JP-listed companies
  3. Financials
  4. Operating margin (%)

(4892)

Market cap
¥6.8B
P/E ratio
-6.2x
Cyfuse develops 3D tissues and organs made entirely from human cells for regenerative medicine, drug discovery, and medical device applications.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Dec 31, 2025-358.5-78.22%
Dec 31, 2024-1,645.9+44.22%
Dec 31, 2023-1,141.2+905.37%
Dec 31, 2022-113.5-1239.26%
Dec 31, 202110-103.68%
Dec 31, 2020-270.7

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat